期刊文献+

周围型小肺腺癌表皮生长因子受体基因突变与高分辨CT、病理亚型的相关性 被引量:9

A comparative study of HRCT and pathological subtype, EGFR gene mutations of peripheral small lung adenocarcinoma
原文传递
导出
摘要 目的 探讨周围型小肺腺癌表皮生长因子受体(EGFR)基因突变类型与术前高分辨CT(HRCT)以及术后病理亚型相关性.方法 北京朝阳医院胸外科2011年12月-2014年11月接受手术切除肺小结节患者156例,其中肺腺癌128例,回顾性分析资料完整的94例浸润性腺癌患者,男37例、女57例,年龄32~ 76岁,平均52.6岁.手术方式为肺叶切除+系统淋巴结清扫或肺局部切除(楔形或肺段)+淋巴结清扫.分析指标包括:术前HRCT、术后病理亚型、淋巴结情况;EGFR、Kras、ALK、FGF9基因表达情况.结果 术后病理腺泡为主型占33.0% (31/94)、乳头状为主型占25.5% (24/94)、附壁生长型占19.1% (18/94)、微乳头状为主13.8% (13/94)、实性为主8.5%(8/94).7例淋巴结阳性,其中N15例(第11~12组)、N22例(第7组和第4组各1例).术后病理基因检测EGFR突变36例(38.3%,36/94),主要为19+和21+.与术前HRCT表现相比,EGFR突变与无突变者差异无统计学意义(x2 =1.411,P=0.703).对于不同EGFR基因突变类型,差异亦无统计学意义(P>0.05).但是EGFR 21阳性者多见于肿瘤进展患者,显著高于EGFR 19阳性者(x2=5.779,P=0.016).结论 EGFR不同基因突变类型在HRCT表现和病理亚型上差异无统计学意义,双肺转移型肺腺癌多有EGFR 21基因突变. Objective To investigate the relationship of the preoperative HRCT,postoperative pathological subtype and EGFR gene mutation types in the patients of small peripheral lung adenocacinoma confirmed by operation.Methods Between December 2011 and November 2014,Ninety-four invasive adenocarcinoma patient were selected from 156 patients with pulmonary nodule underwent operation in Beijing Chaoyang hospital.Among them,there were male 37 cases,female 57 cases,age range from 32 to 76,mean age 52.6.All patients underwent complete anatomical lobectomy or wedge resection or segmentectomy,with systematic mediastinal lymph node dissection.The detection indexes included:preoperative HRCT,postoperative pathological subtypes,lymph node; EGFR,Kras,ALK,FGF9 gene expression and so on.Results Postoperative pathologic acinar predominant accounted for 33.0% (31/94),papillary predominant type accounted for 25.5% (24/94),Lepidic predominant adenocarcinoma accounted for 19.1% (18/94),13.8% (13/94) micro papillary predominant,8.5% (8/94) solid predominant.7 patients with lymph node positive included 5 cases of stations 11-12,1 case of station 4 and 1 case of station 7.36 cases was detected EGFR mutation after operation (38.9%,36/94),mainly 19+ and 21 +.Compared with the preoperative HRCT findings,there was no significant difference in EGFR mutation group and non mutation group(x2 =1.411,P =0.703).For different types of mutations in EGFR gene,there was no statistical difference (P 〉 0.05).But the rate of EGFR 21 positive in progression patients was significantly higher than that of EGFR 19 positive patients (x2 =5.779,P =0.016).Conclusion There were no significant different between the HRCT manifestations and pathological subtypes in the rate of EGFR gene mutation.EGFR 21 gene mutation was found in double lung metastasis commonly.
出处 《中华医学杂志》 CAS CSCD 北大核心 2015年第33期2673-2676,共4页 National Medical Journal of China
基金 北京市教育委员会科技发展计划面上项目(KM201010025017) 吴阶平医学基金会临床科研专项资助基金(320.6750.15052)
关键词 肺肿瘤 受体 表皮生长因子 病理学 Lung neoplasms Receptor,epidermal growth factor Pathology
  • 相关文献

参考文献15

  • 1葛虓俊,高丰,李铭,陈燕,吕凡真,任庆国,滑炎卿.磨玻璃结节中实性成分对肺腺癌术前CT诊断的价值[J].中华医学杂志,2014,94(13):1010-1013. 被引量:26
  • 2Sakurai H, Nakagawa K, Watanabe S, et al. Clinicopathologic features of resected subcentimeter lung cancer [ ] ]. Ann Thorac Surg, 2015,99 (5) : 1731-1738.
  • 3Jiang W, Pang X, Xi J, et al. Clinical outcome of subcentimeter non-small cell lung cancer after surgical resection: single institution experience of 105 patients [ J 1. J Surg Oncol, 2014, 110(3) : 233-238.
  • 4Zhang Y, Sun Y, Shen L, et al. Predictive factors of lymph node status in small peripheral non-small cell lung cancers: tumor histology is more reliable [ J ]. Ann Surg Oncol, 2013,20 ( 6 ) : 1949-1954.
  • 5Glynn C, Zakowski MF, Ginsberg MS. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features? [ J 1. J Thorac Oncol, 2010,5 ( 3 ) : 344-348.
  • 6Yoshida Y, Kokubu A, Suzuki K, et al. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity[ Jl. Jpn J Clin Oncol, 2007,37(12) :907-912.
  • 7Hsu KH, Chen KC, Yang TY, et al. Epidermal growth factor receptor mutation status in stage I lung adenoearcinoma with different image pattems [ J 1. J Thorac Oncol, 2011,6 ( 6 ) : 1066- 1072.
  • 8Yoshida Y, Shibata T, Kokubu A, et al. Mutations of the epidermal growth factor receptor gene in atypical adenomatoushyperplasia and bronchioloalveolar carcinoma of the lung [ J ]. Lung Cancer,2005,50 (1) :1-8.
  • 9Reinmuth N, Jauch A, Xu EC, et al. Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients[ J]. Lung Cancer, 2008,62 ( 2 ) : 193-201.
  • 10宋欣,宋志刚,吕亚莉,钟梅,李向红.细支气管肺泡癌和肺腺癌EGFR基因扩增的研究[J].中国肺癌杂志,2009,12(8):879-883. 被引量:3

二级参考文献24

  • 1吴一龙,蒋国樑,陆舜,周清华,张力,无.支气管肺泡细胞癌之中国共识[J].循证医学,2006,6(4):227-230. 被引量:28
  • 2Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review of current concepts and evolving issues. Arch Pathol Lab Med, 2007, 131(7): 1027-1032.
  • 3Travis WD, Muller-Hermelink H-K, Harris CC, et al. Pathology and genetics of tumours of the Lung, pleural, thymus and heart. Lyon, France: IARC Press, 2004. World Health Organizition Classification of Tumours.
  • 4Dan JR, Biao H, Rafael R, et al. Currmt concepts in bronchioloalveolar carcinoma biology. Clin Cancer Rse, 2006, 12(12): 3698-3704.
  • 5Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small- cell lung cancer.J Clin Oncol, 2004, 22(6): 1103-1109.
  • 6Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 2004, 101 (36): 13306-13311.
  • 7Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res, 2004, 10(12 Pt 2): 4205-4209s.
  • 8Li AR, Chitale D, Riely G J, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression.J Mol Diagn, 2008, 10(3): 242-248.
  • 9Akishi O, Takuo T, Xiaoling L, et al. Protein overexpresion and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol, 2004, 17(8): 895-904.
  • 10Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high- throughput molecular profiling of tumor specimens. Nat Med, 1998, 4(7): 844-847.

共引文献28

同被引文献73

引证文献9

二级引证文献86

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部